205 related articles for article (PubMed ID: 36108149)
41. Antitumor immunity by small extracellular vesicles collected from activated dendritic cells through effective induction of cellular and humoral immune responses.
Matsumoto A; Asuka M; Takahashi Y; Takakura Y
Biomaterials; 2020 Sep; 252():120112. PubMed ID: 32422494
[TBL] [Abstract][Full Text] [Related]
42. BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion.
Liu L; Cheng X; Yang H; Lian S; Jiang Y; Liang J; Chen X; Mo S; Shi Y; Zhao S; Li J; Jiang R; Yang DH; Wu Y
Mol Cancer; 2022 Feb; 21(1):59. PubMed ID: 35193595
[TBL] [Abstract][Full Text] [Related]
43. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8
van Bruggen JAC; Martens AWJ; Fraietta JA; Hofland T; Tonino SH; Eldering E; Levin MD; Siska PJ; Endstra S; Rathmell JC; June CH; Porter DL; Melenhorst JJ; Kater AP; van der Windt GJW
Blood; 2019 Jul; 134(1):44-58. PubMed ID: 31076448
[TBL] [Abstract][Full Text] [Related]
44. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.
Yeh YY; Ozer HG; Lehman AM; Maddocks K; Yu L; Johnson AJ; Byrd JC
Blood; 2015 May; 125(21):3297-305. PubMed ID: 25833959
[TBL] [Abstract][Full Text] [Related]
45. LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Nguyen PH; Fedorchenko O; Rosen N; Koch M; Barthel R; Winarski T; Florin A; Wunderlich FT; Reinart N; Hallek M
Cancer Cell; 2016 Oct; 30(4):610-622. PubMed ID: 27728807
[TBL] [Abstract][Full Text] [Related]
46. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic Approach for the Elucidation of Elevated Plasma Small Extracellular Vesicle (sEV) Concentration in Cancer.
Yamamoto A; Toba M; Takahashi Y; Takakura Y
J Pharm Sci; 2023 Jul; 112(7):1967-1974. PubMed ID: 37001861
[TBL] [Abstract][Full Text] [Related]
48. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.
Filip AA; Ciseł B; Wąsik-Szczepanek E
Clin Exp Med; 2015 Feb; 15(1):73-83. PubMed ID: 24337970
[TBL] [Abstract][Full Text] [Related]
49. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
Reinart N; Nguyen PH; Boucas J; Rosen N; Kvasnicka HM; Heukamp L; Rudolph C; Ristovska V; Velmans T; Mueller C; Reiners KS; von Strandmann EP; Krause G; Montesinos-Rongen M; Schlegelberger B; Herling M; Hallek M; Fingerle-Rowson G
Blood; 2013 Jan; 121(5):812-21. PubMed ID: 23118218
[TBL] [Abstract][Full Text] [Related]
50. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.
Smith AL; Skupa SA; Eiken AP; Reznicek TE; Schmitz E; Williams N; Moore DY; D'Angelo CR; Kallam A; Lunning MA; Bociek RG; Vose JM; Mohamed E; Mahr AR; Denton PW; Powell B; Bollag G; Rowley MJ; El-Gamal D
JCI Insight; 2024 May; 9(10):. PubMed ID: 38775157
[TBL] [Abstract][Full Text] [Related]
51. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
Blood; 2012 May; 119(20):4708-18. PubMed ID: 22474251
[TBL] [Abstract][Full Text] [Related]
52. Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia.
Goral A; Sledz M; Manda-Handzlik A; Cieloch A; Wojciechowska A; Lachota M; Mroczek A; Demkow U; Zagozdzon R; Matusik K; Wachowska M; Muchowicz A
Exp Hematol Oncol; 2023 Oct; 12(1):89. PubMed ID: 37817276
[TBL] [Abstract][Full Text] [Related]
53. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
54. Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.
Parigger T; Gassner FJ; Scherhäufl C; Bakar AA; Höpner JP; Hödlmoser A; Steiner M; Catakovic K; Geisberger R; Greil R; Zaborsky N
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206229
[TBL] [Abstract][Full Text] [Related]
55. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1.
Li M; Soder R; Abhyankar S; Abdelhakim H; Braun MW; Trinidad CV; Pathak HB; Pessetto Z; Deighan C; Ganguly S; Dawn B; McGuirk J; Dunavin N; Godwin AK
J Extracell Vesicles; 2021 Feb; 10(4):e12067. PubMed ID: 33598108
[TBL] [Abstract][Full Text] [Related]
56. Syntenin-1-mediated small extracellular vesicles promotes cell growth, migration, and angiogenesis by increasing onco-miRNAs secretion in lung cancer cells.
Kim O; Hwangbo C; Tran PT; Lee JH
Cell Death Dis; 2022 Feb; 13(2):122. PubMed ID: 35136055
[TBL] [Abstract][Full Text] [Related]
57. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
Nunes C; Wong R; Mason M; Fegan C; Man S; Pepper C
Clin Cancer Res; 2012 Feb; 18(3):678-87. PubMed ID: 22190592
[TBL] [Abstract][Full Text] [Related]
58. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Nishida T; Hudecek M; Kostic A; Bleakley M; Warren EH; Maloney D; Storb R; Riddell SR
Clin Cancer Res; 2009 Jul; 15(14):4759-68. PubMed ID: 19567591
[TBL] [Abstract][Full Text] [Related]
59. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia.
Mancikova V; Peschelova H; Kozlova V; Ledererova A; Ladungova A; Verner J; Loja T; Folber F; Mayer J; Pospisilova S; Smida M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217767
[TBL] [Abstract][Full Text] [Related]
60. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.
Giannopoulos K; Mertens D; Bühler A; Barth TF; Idler I; Möller P; Kröber A; Greiner J; Chocholska S; Dmoszyñska A; Roliñski J; Döhner H; Stilgenbauer S; Schmitt M
Leukemia; 2009 Mar; 23(3):519-27. PubMed ID: 19092852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
